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Studies indicate that West African and Congo basin isolates of monkeypox virus (MPXV) are genetically distinct. Here, we show Congo
basin MPXV-ZAI-V79 is more virulent for cynomolgus monkeys as compared to presumed West African MPXV-COP-58. This finding may
explain the lack of case-fatalities in the U.S. 2003 monkeypox outbreak, which was caused by a West African virus. Virulence differences
between West African and Congo basin MPXV are further supported by epidemiological analyses that observed a similar prevalence of
antibodies in non-vaccinated humans in both regions, while >90% of reported cases occurred in the Congo basin, and no fatal cases were
observed outside of this region. To determine the basis for this difference in virulence, we sequenced the genomes of one human West African
isolate, and two presumed West African isolates and compared the sequences to Congo basin MPXV-ZAI-96-I-16. The analysis identified
D10L, D14L, B10R, B14R, and B19R as possible virulence genes, with D14L (ortholog of vaccinia complement protein) as a leading
candidate.
D 2005 Elsevier Inc. All rights reserved.Keywords: Monkeypox; Genomic sequences; Genetic diversity; Virulence genes; Non-human primatesIntroduction
MPXV causes a smallpox-like disease in humans and
may threaten the population either as a zoonotic infection or
through a criminal event. The case-fatality rate of human0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.05.030
* Corresponding author. Fax: +1 314 977 8717.
E-mail address: bullerrm@slu.edu (R.M.L. Buller).
1 These authors contributed equally to the manuscript.monkeypox in a 1980s prospective study in the Democratic
Republic of the Congo (DRC former Zaire) was approx-
imately 10% (Jezek and Fenner, 1988), compared to variola
virus (VARV) smallpox, which ranged from >1% to about
15% in Africa and to approximately 30% in Asia (Fenner et
al., 1988). Unlike smallpox, which had secondary attack
rates ranging to 60%, human monkeypox during the 1980s
prospective study was about 10%, with interhuman trans-
mission rarely over two or three generations (Jezek et al.,
1986). Recent retrospective studies suggest that disease005) 46 – 63
N. Chen et al. / Virology 340 (2005) 46–63 47incidence is increasing due to encroachment of humans into
habitats of animal reservoirs for MPXV (Mukinda et al.,
1997; Hutin et al., 2001). Also, the first outbreak in the
Western hemisphere occurred in the U.S. Midwest from
April to June of 2003 (Reed et al., 2004). MPXVentered the
U.S. in a shipment of African rodents from Ghana (West
Africa) destined for the pet trade. At a pet distribution
center, prairie dogs became infected and in turn were
responsible for 72 confirmed or suspected cases of human
monkeypox. Unlike African outbreaks, the U.S. outbreak
resulted in no fatalities and there was no documented
human-to-human transmission (Reed et al., 2004). This less
severe epizootic could be due to higher natural resistance of
the U.S. population, a healthier patient population lacking
background infections, and/or better supportive care for
patients. There is, however, a significant possibility that this
variability in pathogenicity is secondary to strain-specific
differences in the virulence of the infecting virus.
The U.S. Midwest isolates belong to the West African
MPXV group which is genetically distinct from Congo
basin isolates as determined by restriction fragment length
polymorphisms (RFLP) and DNA sequencing analysis of
the hemagglutinin and TNFR genes (Mukinda et al., 1997;
Esposito and Knight, 1985; Esposito and Fenner, 2001).
Virulence differences between West African and Congo
basin MPXVare supported by epidemiological analyses that
observed a similar prevalence of antibodies in non-
vaccinated humans in both regions (Jezek and Fenner,
1988), while >90% of reported cases occurred in the Congo
basin, and no fatal cases were observed outside of this
region (Esposito and Fenner, 2001). In this study, we
formally compare the virulence of West African and Congo
basin isolates of MPXV in cynomolgus monkeys, and use
comparative genomics to identify and characterize predicted
genes that may be responsible for virulence differences.Table 1
Aerosol infection of cynomolgus monkeys with West and Congo basin
isolates monkeypox virus
MPXV isolate Aerosol dose
(PFU/monkey)a
Morbidity
(Day 7)b
Mortality Mean day
of death
COP-58 110 0/3 0/3 –
20,000 0/3c 0/3 –
ZAI-V79 90 2/3 0/3 –
50,000 3/3 3/3 10 T 1
a An aerosol route of challenge was used, as it is possibly the major route
for a person-to-person transmission of MPXV. The aerosol challenge
particle size was 1–3 Am.
b Exanthem, enanthem, cough, depression.
c Late enanthem ¨10 days.Results and discussion
Virulence of West African and Congo basin isolates of
MPXV in non-human primates
We examined the virulence of MPXV-COP-58 (COP-58)
and a Congo basin isolate MPXV-ZAI-V79 (ZAI-V79) by
aerosol infection of cynomolgus monkeys with high and
low doses of virus. MPXV-COP-58, although derived from
a primate shipped from Singapore to Copenhagen which
developed disease 62 days after arriving in Copenhagen, is
presumed to be of West African origin by virtue of
restriction enzyme profiles (Esposito and Knight, 1985),
geographically-restricted primate anti-orthopoxvirus sero-
prevalences (Arita et al., 1972), and historic inferences
(Fenner et al., 1989). This supposition is strengthened by the
sequence analysis provided here. MPXV-COP-58 caused no
deaths and little morbidity following aerosol challenge,
whereas infections with the Congo basin isolate resulted insevere morbidity at the low dose and uniform mortality at
the high dose (Table 1). These data further support the
contention that the Congo basin isolates are more virulent
for humans than those from West Africa.
Genome sequencing of West African isolates SL-V70,
WRAIR-61, and COP-58
To identify the putative genetic basis of this difference in
virulence, we needed to acquire the genomic sequences of
West African isolates and compare them to those from
MPXV-ZAI-96-I-16 (ZAI-96), the sole Congo basin group
member whose genomic sequence is available in GenBank
(Shchelkunov et al., 2001, 2002). Therefore, we sequenced
the genomes of West African isolates SL-V70, WRAIR-61,
and COP-58 and obtained contiguous consensus sequences
of 198,756, 199,195, and 199,469 nucleotides, respectively.
The genomes were resolved to an average 4.8-fold or greater
redundancy (lowest coverage 2-fold); we did not sequence
the palindromic hairpin terminal loop (¨80 bp) of each end
of the genome. The first nucleotide of each genomic
sequence of SL-V70, WRAIR-61, and COP-58 was
equivalent to nucleotide 160, 155, and 149 of the genomic
sequence of VACV-COP, respectively. This position was 25,
30, and 36 nucleotides, respectively, beyond the end of the
first primer used to amplify the sequencing templates.
Genetic diversity between West African and Congo basin
isolates
Based upon multiple nucleic acid sequence alignments of
the core conserved genomic region of each orthopoxvirus
(OPV) species, we determined the evolutionary relation-
ships between these viruses which are shown in Fig. 1A. To
further examine the relatedness of the MPXV isolates, we
compared the genome of West African isolate SL-V70 with
the genomes of the other MPXV isolates. We chose SL-V70
as the prototypic West African isolate because it was
isolated from a case of human monkeypox in Sierra Leone
(Foster et al., 1972). Fig. 1B is a graphic representation of
the substitutions, insertions, and deletions (InDel) observed
between the aligned genomes. SL-V70 is more closely
Fig. 1. Genomic comparison of West African and Congo basin isolates of MPXV. (A) OPV phylogenetic predictions based upon the multiple nucleic acid
sequence alignments of the core genomic region of each representative orthopoxvirus species, strain, or isolate. Bootstrap resampling confidence percentage
based on 1000 replicates are displayed at each branch point. Branch lengths are proportional to the number of nucleotide changes. (B) CLUSTALW software
was used to align the genomes of SL-V70, COP-58, WRAIR-61, and ZAI-96 and the alignment was manually optimized using Base-By-Base (Brodie et al.,
2004). Each mismatched base was identified as a substitution (blue bar), deletion (red bar), or insertion (green bar) relative to a consensus; blue bars in all
genomes indicate no consensus. InDels were counted as one mismatch regardless of size. The scale is such that several substitutions in close proximity may
generate a single blue bar. (C) Summary of nucleotide difference comparisons: upper (grey) = gap number (segments) / total gap length; lower = number
substitutions / number identical (non-gap) residues / percent difference (includes number of gaps).
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There are no differences in the set of genes predicted for SL-
V70, COP-58, and WRAIR-61, and examination of the
minor sequence differences among them does not support
any biological consequence for these changes (Table S1 inAppendix A). A similar comparative analysis between COP-
58 and WRAIR-61 shows that they are more closely related
to each other than to SL-V70, but are distinguished from
each other by the number and position of minor repeat
elements and a series of polyA/T tracts distributed along the
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closely related isolates in molecular epidemiological studies
(Supporting online data in Appendix A). Fig. 1C summa-
rizes percent difference values for individual paired com-
parisons. The SL-V70, COP-58, and WRAIR-61 isolates
show 0.55–0.56% difference with ZAI-96 as compared to
0.01–0.07% nucleotide difference among themselves. For
comparison, we observe the following OPV intraspecies
nucleotide difference values: 0.2% VARV (major strains
Bangladesh-1975 [BSH-75] and India-1967); 0.4% VARV
(BSH-75, major strain and Garcia-1966, minor strain); 1.1%
VACV (strains WR and COP); 0.4% ECTV (NAVand MOS
isolates), and a 0.1% camelpox virus (M-96 and CMS
isolates). An interspecies comparison of SL-V70 with
ECTV-MOS, VACV-COP, VARV-BSH-75, and CPXV-BR
yields <4.9% nucleotide difference. These intraspecies
nucleotide difference values are reflected in the branch
length differences of the evolutionary tree shown in Fig. 1A.
This high level of identity among OPVs is consistent with
the genes having a similar function in all OPV. In summary,
there is significantly greater sequence diversity between the
West African SL-V70 and Congo basin ZAI-96 isolates than
between SL-V70 and the two other presumptive WestFig. 2. Physical map of SL-V70. Predicted genes are numbered and shown as stra
shown with staggered arrows to represent frame changes and are labeled A–Z. O
shown in kilobases. The thick line represents the ITR.African isolates (COP-58 and WRAIR-61) indicating that
analyzed West and Congo basin isolates belong to separate
clades; this confirms and extends the MPXV RFLP studies
of others (Mukinda et al., 1997; Douglass et al., 1994;
Esposito and Knight, 1985).
Comparison of the West African SL-70 and Congo basin
ZAI-96 genomes
The preceding data show that West African and Congo
Basin MPXV isolates differ in virulence for cynomolgus
monkeys, and that they are genetically distinct. To
identify genes potentially responsible for the observed
virulence difference, more extensive comparative analyses
were carried out between West African SL-V70 and
Congo basin ZAI-96. Within the SL-V70 genome, we
predict 171 functional unique genes, 26 non-functional
open reading frames (ORF) regions, and small vestiges of
an additional 10 ORFs (Fig. 2, Tables 2 and 3). The
ZAI-96 genome is predicted to contain 173 unique genes
(Table 2) and 16 truncated ORFs. SL-V70 and ZAI-96
share 170 unique orthologs that are on average more than
99.4% identical at the protein level. Comparisons ofight arrows; regions containing fragments of larger genes in other OPVs are
pen arrowheads indicate an ORF split over 2 lines of the diagram. Scale is
Table 2
Predicted ORFs in SL-V70
SL-70a ZAI-96 orthologb Predicted motif/function
Name Lengthc Startd Stope Name Length Identical Identity (%)
1 246 1510 770 J1L 246 246 100.0 SecP/CC-Chemokine BP (C23L/B29R)f
2 349 2686 1637 J2L 348 345 98.9 SecP/TNF BP (crmB) (BR005/226)
3 590 4548 2776 J3L 587 581 99.2 Ankyrin/unknown (BR-006/225)
4 437 6008 4695 D1L 437 432 98.9 Ankyrin/unknown (BR-017)
5g 176 6653 6123 – – – – Unknown (BR-018)
6g 153 7863 7402 – – – – Unknown (C16L/B22R)
7 142 9076 9504 D3R 142 142 100.0 Growth factor (C11R)
8 242 11,081 11,809 D5R 242 240 99.2 RING finger/apoptosis (MOS-012)
9 126 12,392 12,012 D6L 126 126 100.0 SecP/IL-18 BP (BSH-D7L)
10 660 14,434 12,452 D7L 660 650 98.5 CHO Host range (BSH-D8L)
11 64 14,764 14,570 D8L 64 63 98.4 Retroviral pseudoprotease (BR-026)
12 630 16,803 14,911 D9L 630 626 99.4 Ankyrin (C9L)
13 167 17,964 17,461 D10L 150 147 98.0 Host range (C7L)
14 159 18,617 18,138 D11L 153 151 99.3 Unknown (C6L)
15 206 19,381 18,761 D12L 206 204 99.0 Unknown (C5L)
16 316 20,376 19,426 D13L 315 312 98.7 IL-1 receptor antagonist (C4L)
– – – – D14Lh 216 – – Inhibitor of complement enzymes (C3L)
17 214 21,561 20,917 D19L 214 213 99.5 Unknown (C1L)
18 117 21,960 21,607 P1L 117 117 100.0 Cytoplasmic P/virulence (N1L)
19 177 22,620 22,087 P2L 177 176 99.4 a-Amanitin sensitivity (N2L)
20 446 23,988 22,648 O1L 442 439 99.3 Ankyrin/unknown (M1L)
21 220 24,720 24,058 O2L 220 218 99.1 Unknown (M2L)
22 284 25,679 24,825 C1L 284 283 99.7 Ankyrin/host range (K1L)
23 374 27,422 26,298 C2L 375 373 99.5 Serpin (SPI-3)/unknown (K2L)
24 424 29,041 27,767 C4L 424 423 99.8 Phospholipase D-like/unknown (K4L)
25 276 29,899 29,069 C5L 276 274 99.3 MG lipase-like/unknown (BR045)
26 149 30,035 30,484 C6R 149 146 98.0 Unknown (K7R)
27 219 31,206 30,547 C7L 219 216 98.6 Apoptosis inhibitor (F1L)
28 151 31,673 31,218 C8L 151 151 100.0 dUTPase (F2L)
29 492 33,148 31,670 C9L 487 477 98.4 Kelch-like/unknown (F3L)
30 319 34,118 33,159 C10L 319 319 100.0 R. Reductase-small (F4L)
31 343 35,180 34,149 C11L 343 339 98.8 Major membrane protein (F5L)
32 73 35,358 35,137 C12L 73 73 100.0 Unknown (F6L)
33 74 35,598 35,374 C13L 74 74 100.0 Unknown (F7L)
34 64 35,944 35,750 C14L 64 64 100.0 Proline rich P/unknown (F8L)
35 212 36,639 36,001 C15L 212 212 100.0 Putative MP/unknown (F9L)
36 439 37,945 36,626 C16L 439 438 99.8 Ser/Thr kinase/morphogen (F10L)
37 354 39,032 37,968 C17L 354 353 99.7 Unknown (F11L)
38 635 40,983 39,076 C18L 635 630 99.2 IEV, actin tail, microtubule inter. (F12L)
39 372 42,144 41,026 C19L 372 370 99.5 Phospholipase/EEV (F13L)
40 73 42,383 42,162 C20L 73 73 100.0 Unknown (F14L)
41 158 43,131 42,655 C21L 158 158 100.0 Unknown (F15L)
42 231 43,833 43,138 C22L 231 231 100.0 MP/unknown (F16L)
43 101 43,896 44,201 C23R 101 101 100.0 IMV, DNA bound PP (F17R)
44 479 45,637 44,198 F1L 479 477 99.6 Poly(A) pol large (E1L)
45 737 47,847 45,634 F2L 737 736 99.9 Unknown (E2L)
46 153 48,432 47,971 F3L 153 153 100.0 PKR/OAS inhibitor (E3L)
47 259 49,377 48,598 F4L 259 257 99.2 RNA pol (RPO30) VITF-01 (E4L)
48 567 50,150 51,853 F5R 567 565 99.7 Unknown (E6R)
49 166 51,935 52,435 F6R 166 166 100.0 Myristyl MP/EEV (E7R)
50 273 52,539 53,360 F7R 273 272 99.6 ER-localized MP/unknown (E8R)
51 1006 56,387 53,367 F8L 1006 1002 99.6 DNA pol (E9L)
52 95 56,419 56,706 F9R 95 93 97.9 IMV, -S-S-bond PW (E10R)
53 129 57,090 56,701 F10L 129 129 100.0 IMV, core (E11L)
54 665 59,074 57,077 Q1L 665 663 99.7 MP/unknown (O1L)
55 108 59,447 59,121 Q2L 108 108 100.0 Glutaredoxin/unknown (O2L)
56 312 60,532 59,594 I1L 312 312 100.0 IMV, core, morphogen (I1L)
57 73 60,760 60,539 I2L 73 73 100.0 MP/unknown (I2L)
58 269 61,570 60,761 I3L 269 268 99.6 DNA-binding PP (I3L)
59 771 63,967 61,652 I4L 771 764 99.1 R. Reductase-large (I4L)
60 79 64,235 63,996 I5L 79 79 100.0 MP/IMV (I5L)
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SL-70a ZAI-96 orthologb Predicted motif/function
Name Lengthc Startd Stope Name Length Identical Identity (%)
61 382 65,402 64,254 I6L 382 381 99.7 Telomere BP (I6L)
62 423 66,666 65,395 I7L 423 423 100.0 IMV, core, CP (I7L)
63 676 66,672 68,702 I8R 676 675 99.9 RNA helicase, NPH-II (I8R)
64 591 70,481 68,706 G1L 591 587 99.5 Metalloprotease (G1L)
65 220 70,807 71,469 G3R 220 220 100.0 VLTF (G2R)
66 111 70,813 70,478 G2L 111 111 100.0 SecP/unknown (G3L)
67 124 71,813 71,439 G4L 124 124 100.0 IMV, -S-S-bond PW (G4L)
68 434 71,816 73,120 G5R 434 431 99.3 Unknown (G5R)
69 63 73,129 73,320 G6R 63 63 100.0 RNA pol (RPO7) (G5.5R)
70 165 73,320 73,817 G7R 165 162 98.2 Unknown (G6R)
71 371 74,897 73,782 G8L 371 370 99.7 IMV, core, matrix (G7L)
72 260 74,928 75,710 G9R 260 260 100.0 VLTF-1 (G8R)
73 340 75,730 76,752 G10R 340 340 100.0 Myristyl MP/unknown (G9R)
74 250 76,753 77,505 M1R 250 250 100.0 Myristyl MP/IMV (L1R)
75 92 77,537 77,815 M2R 92 91 98.9 MP/unknown (L2R)
76 344 78,825 77,791 M3L 344 343 99.7 Unknown (L3L)
77 251 78,850 79,605 M4R 251 251 100.0 IMV, core, ssDNA binding (L4R)
78 128 79,615 80,001 M5R 128 128 100.0 MP/unknown (L5R)
79 152 79,958 80,416 L1R 152 151 99.3 MP/IMV, morphogen (J1R)
80 177 80,436 80,969 L2R 177 175 98.9 Thymidine kinase (J2R)
81 333 81,035 82,036 L3R 333 331 99.4 Poly(A) poly-small (VP39) (J3R)
82 185 81,951 82,508 L4R 185 185 100.0 RNA pol (RPO22) (J4R)
83 133 82,971 82,570 L5L 133 133 100.0 MP/unknown (J5L)
84 1286 83,078 86,938 L6R 1286 1278 99.4 RNA pol (RPO147) (J6R)
85 171 87,450 86,935 H1L 171 171 100.0 Tyr/Ser phosphatase/unknown (H1L)
86 189 87,464 88,033 H2R 189 188 99.5 MP/unknown (H2R)
87 324 89,011 88,037 H3L 324 322 99.4 MP/IMV (H3L)
88 795 91,399 89,012 H4L 795 791 99.5 RNA pol assoc P 94 (H4L)
89 210 91,584 92,216 H5R 213 208 97.7 VLTF-4 (H5R)
90 314 92,217 93,161 H6R 314 313 99.7 DNA topo type I (H6R)
91 144 93,199 93,633 H7R 146 143 99.3 MP/unknown (H7R)
92 845 93,677 96,214 E1R 845 843 99.8 Capping enzyme-large (D1R)
93 233 96,606 97,307 E3R 233 233 100.0 IMV, core (D3R)
94 146 96,613 96,173 E2L 146 146 100.0 IMV, core (D2L)
95 218 97,307 97,963 E4R 218 218 100.0 Uracil-DNA glycosylase (D4R)
96 785 97,995 100,352 E5R 785 784 99.9 N. triphosphat./DNA replication (D5R)
97 637 100,392 102,305 E6R 637 635 99.7 VETF-small (D6R)
98 161 102,332 102,817 E7R 161 161 100.0 RNA pol (RPO18) (D7R)
99 304 103,694 102,780 E8L 304 302 99.3 MP/IMV, attach (D8L)
100 213 103,736 104,377 E9R 213 213 100.0 MutT-like/unknown (D9R)
101 248 104,374 105,120 E10R 248 248 100.0 MutT-like/unknown (D10R)
102 631 107,016 105,121 E11L 631 627 99.4 NPH-I/IMV (D11L)
103 287 107,914 107,051 E12L 287 287 100.0 Capping enzyme-small (D12L)
104 551 109,600 107,945 E13L 551 548 99.5 IMV, morphogen, rif resist (D13L)
105 150 110,076 109,624 A1L 150 150 100.0 VLTF-2 (A1L)
106 224 110,771 110,097 A2L 224 223 99.6 VLTF-3 (A2L)
107 77 111,001 110,768 A3L 77 77 100.0 Thioredoxin/-S-S-bond PW (A2.5L)
108 644 112,950 111,016 A4L 644 644 100.0 IMV, core, precursor of p4b (A3L)
109 281 113,848 113,003 A5L 281 278 98.9 IMV, matrix, morphogen (A4L)
110 161 113,886 114,371 A6R 161 161 100.0 RNA pol (RPO19) (A5R)
111 372 115,486 114,368 A7L 372 372 100.0 Unknown (A6L)
112 710 117,642 115,510 A8L 710 709 99.9 VETF-large (A7L)
113 292 117,696 118,574 A9R 292 290 99.3 VITF-3-S (A8R)
114 112 118,893 118,555 A10L 100 99 88.4 MP/IMV, morphogen (A9L)
115 891 121,569 118,894 A11L 891 888 99.7 IMV, core, precursor of p4a (A10L)
116 318 121,584 122,540 A12R 318 318 100.0 MP/unknown (A11R)
117 190 123,114 122,542 A13L 190 190 100.0 IMV, core (A12L)
118 70 123,350 123,138 A14L 70 70 100.0 MP/IMV (A13L)
119 90 123,728 123,456 A15L 90 90 100.0 MP/IMV, morphogen (A14L)
120 53 123,906 123,745 A15.5L 53 53 100.0 MP/IMV, virulence (A14.5L)
121 94 124,180 123,896 A16L 94 94 100.0 Unknown (A15L)
(continued on next page)
Table 2 (continued)
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SL-70a ZAI-96 orthologb Predicted motif/function
Name Lengthc Startd Stope Name Length Identical Identity (%)
122 377 125,297 124,164 A17L 377 374 99.2 Myristyl P/unknown (A16L)
123 204 125,914 125,300 A18L 204 203 99.5 MP/IMV, morphogen (A17L)
124 492 125,929 127,407 A19R 492 489 99.4 IMV, core, DNA helicase (A18R)
125 77 127,621 127,388 A20L 77 76 98.7 Unknown (A19L)
126 426 127,968 129,248 A22R 426 425 99.8 DNA pol processivity (A20R)
127 115 127,969 127,622 A21L 115 114 99.1 SecP/unknown (A21L)
128 187 129,178 129,741 A23R 187 187 100.0 Holiday junction resolvase (A22R)
129 382 129,761 130,909 A24R 382 381 99.7 VITF-3L (A23R)
130 1164 130,906 134,400 A25R 1164 1160 99.7 RNA pol (RPO132) (A24R)
131 506 139,626 138,106 A28L 520 501 96.4 MP/IMV, P4c IF (BSH A30L)
132 110 140,009 139,677 A29L 110 108 98.2 MP/IMV (A27L)
133 146 140,450 140,010 A30L 146 146 100.0 SecP TM/unknown (A28L)
134 305 141,368 140,451 A31L 305 301 98.7 RNA pol (RPO35) (A29L)
135 78 141,567 141,331 A32L 77 76 97.4 IMV, matrix, morphogen (A30L)
136 142 141,727 142,155 A33R 142 140 98.6 Unknown (A31R)
137 42 141,728 141,600 A32.5L 42 42 100.0 Unknown (A30.5L)
138 300 143,024 142,122 A34L 300 298 99.3 ATPase/DNA packaging (A32L)
139 181 143,052 143,597 A35R 181 180 99.5 MP/CEV, EEV (A33R)
140 168 143,602 144,108 A36R 168 167 99.4 MP/CEV, EEV (A34R)
141 176 144,152 144,682 A37R 176 175 99.4 Unknown (A35R)
142 228 144,728 145,414 A38R 212 208 98.1 MP/IEV (A36R)
143 268 145,466 146,272 A39R 268 264 98.5 Unknown (A37R)
144 277 147,357 146,524 A40L 277 275 99.3 MP, CD47-like/unknown (A38L)
145 221 148,758 148,093 A41L 221 219 99.1 SecP/virulence (A41L)
146 133 148,961 149,362 A42R 133 133 100.0 Profilin-like (A42R)
147 196 149,400 149,990 A43R 197 193 98.5 MP/unknown (A43R)
148 74 150,010 150,234 A44R 74 73 98.7 Unknown (MVA-156R)
149 346 151,370 150,330 A45L 346 345 99.7 Hydroxysteroid DH (A44L)
150 125 151,417 151,794 A46R 125 125 100.0 Superoxide dismutase-like (A45R)
151 240 151,784 152,506 A47R 240 239 99.6 Inhibits NF-nB activation (A46R)
152 204 153,459 154,073 A49R 204 203 99.5 Thymidylate kinase (A48R)
153 559 154,642 156,321 A50R 554 554 100.0 DNA ligase (A50R)
154 334 156,362 157,366 A51R 334 331 99.1 Unknown (A51R)
155 313 160,850 161,791 B2R 313 310 99.0 MP/CEV, EEV, HA (A56R)
156 303 162,553 163,464 B3R 299 299 100.0 Ser/Thr kinase/unknown (B1R)
157 505 163,520 165,037 B4R 503 500 99.4 Unknown (B2R/B3R)
158 564 165,226 166,920 B5R 561 559 99.1 Ankyrin/unknown (B4R)
159 317 167,024 167,977 B6R 317 316 99.7 MP/CEV, EEV (B5R)
160 176 168,049 168,579 B7R 176 174 98.9 MP/unknown (B6R)
161 182 168,617 169,165 B8R 182 180 98.9 ER P/virulence (B7R)
162 267 169,220 170,023 B9R 267 267 100.0 SecP/IFN-g BP (B8R)
– – – – B10Rh 221 – Virulence factor (BR-203)
163g,i 98 171,559 171,855 – – – – Unknown (COP-B11R)
164 282 171,921 172,769 B11R 282 280 99.3 Ser/Thr kinase/unknown (B12R)
165 344 172,869 173,903 B12R 344 343 99.7 Serpin (SPI-2)/apoptosis (BR-207)
166 149 174,030 174,479 B13R 149 146 98.0 MP/unknown (B15R)
– – – – B14Rh 326 – – IL-1h BP (BR-209)
167 352 176,361 177,419 B16R 352 351 99.7 IFN-a/h BP (B19R)
168 787 177,488 179,851 B17R 793 781 98.5 Ankyrin/unknown (BSH-B18R)
169 397 180,861 182,054 B19R 357 352 98.6 Serpin (SPI-1)/unknown (C12L)
170 190 182,226 182,798 B20R 190 187 98.4 MP/unknown (BR-218)
171 1880 183,055 188,697 B21R 1879 1861 99.0 MP/unknown (BSH B22R)
172 153 190,894 191,355 N1R 153 152 99.4 Unknown (B22R)
173 176 192,104 192,634 N3R 176 174 98.9 Unknown (BR-018)
174 437 192,749 194,062 N4R/D1L 437 432 98.9 Ankyrin/unknown (BR-017)
175 590 194,209 195,981 J1R 587 581 99.2 Ankyrin/unknown (BR-006/225)
176 349 196,071 197,120 J2R 348 345 98.9 SecP/TNF BP (crmB) (BR-005/226)
177 246 197,247 197,987 J3R 246 246 100.0 SecP/CC chemokine BP (C23L/B29R)
Table 2 (continued)
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Table 3
Fragmented ORFs of VL-V70 genome
Region Longest OPV ortholog Motif/putative function
A/Y CPXV-BR-016 (764aa) Ankyrin motif/unknown
B/Z CMLV-M96-006 (237aa) MAR assoc Pa/unknown
C CPXV-BR-020 (170aa) Unknown
D CPXV-BR-022 (331aa) IL-1 receptor antagonistb
E VACV-COP-C8L (184aa) Unknown
F CPXV-BR-035 (512aa) Kelch-like/unknown
G VACV-COP-K3L (88aa) IFN resistance
H CPXV-BR-071 (319aa) Virosome component
I CPXV-BR-158 (1284aa) A-type inclusion body
J CPXV-BR-176 (409aa) Semaphorin
K VACV-COP-A40R (168aa) Lectin/virulence
L CPXV-BR-185 (244aa) Unknown
M CPXV-BR-187 (162aa) Unknown
N CPXV-BR-190 (190aa) TLR signaling inhibitor
O CPXV-BR-191 (186aa) TNF binding protein
P CPXV-BR-193 (563aa) Kelch-like/unknown
Q CPXV-BR-195 (197aa) Guanylate kinase
R CPXV-BR-203 (225aa) Virulence factor
S CPXV-BR-204 (501aa) Kelch-like/unknown
T ECTV-MOS-163 (328aa) IL-1h binding protein
U CPXV-BR-210 (340aa) Unknown
V ECTV-MOS-167 (559aa) Kelch-like/unknown
W CPXV-BR-221 (320aa) TNF binding protein
X CPXV-GIR-K3R (167aa) TNF binding protein
a N-methyl-d-aspartate receptor-associated protein.
b Kluczyk et al., 2002.
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ORFs revealed no major differences (Supporting online
data in Appendix A).
We identified 170 InDels of a combined length of 9629
nucleotides and 852 substitution mutations out of a total of
193,094 nucleotides when comparing aligned genomes of
SL-V70 and ZAI-96. One hundred and forty-seven InDels
and 192 substitutions are in intergenic regions andNotes to Table 2:
Abbreviations: SecP, secreted protein; BP, binding protein; CHO, Chinese hams
interaction; MP, membrane protein; IEV, intracellular enveloped virion; EEV, e
dsRNA-dependent protein kinase; OAS, 2V–5V oligoadenylate synthetase; VITF, v
pathway; IMV, intracellular mature virion; morphogen, morphogenesis; N tripho
transcription factor; topo, topoisomerase; VETF, viral early transcription factor; a
transmembrane; DH, dehydrogenase; HA, hemagglutinin.
Predictions: secreted proteins by SignalP V1.1; membrane proteins by TMpred.
a DNA encoding remnants of CPXV-BR-001, -002, -063, -174, -216, -228, -22
were not annotated.
b ZAI-96 genome was reannotated as described in the Materials and methods
present in other poxviruses or small predicted ORFs on the non-coding strand. W
D2L, D4L, D15L, D16L, D17L, D18L, C3L, A26L, A27L, A48R, B1R, B15L,
c Length, number of aa in ORF.
d Start, first nucleotide of start codon.
e Stop, last nucleotide of stop codon.
f Orthologus ORF in the VACV-COP, unless otherwise indicated (MOS, ECTV-M
VACV-MVA, and ZAI, ZAI-96).
g An ortholog not present in the corresponding region of ZAI-96.
h An ortholog is not present in SL-V70.
i SL-V70 ORF 163 is the single gene predicted in the SL-V70 isolate, and a
predicted protein range in size from 72–106 due to a highly variable N-terminal r
approximately one third into the ORF, induces a frameshift that results in an early
has not been characterized for this predicted ORF, it is not possible to predict w
Database searches with these predicted proteins failed to yield any significant mafragmented genes. Five InDels and 321 substitutions occur
in 84 genes with functions thought to be essential for virus
replication in standard tissue culture cell lines (e.g. functions
mainly necessary for transcribing mRNA, replicating the
genomic DNA, assembling infectious virions, etc.). These
genes are highly conserved in all sequenced OPVs and
mainly map to a central conserved region (Table 4; see
footnote b for map location in SL-V70). A further 16 genes
that encode similar functions map to the left and right
terminal regions of the genome, and contain 63 substitutions
and 4 InDels. Because SL-V70 and ZAI-79 show similar
kinetics of replication and cell-to-cell spread in tissue
culture (Fig. S1 in Appendix A), we think it less likely
that mutations located in these genes are responsible for the
virulence difference noted between COP-58 and ZAI-79 in
Table 1.
The Virulence Ortholog family of genes
We hypothesize the observed virulence phenotype maps
to a gene(s) in the terminal regions of the MPXV genome
that is important for maximizing virus replication and/or
spread within the tested non-human primate species. This
group of 56 genes of known and unknown functions is
collectively referred to as the Virulence Ortholog family,
and includes 3 genes only present in ZAI-96 and 53 genes
present in both SL-V70 and ZAI-96. There are 14 InDels
and 276 substitutions in the 53 genes common to both
isolates. These mutations are responsible for 61 conserva-
tive, 93 non-conservative, and 121 silent aa changes and
changes in predicted lengths of 16 proteins that are mainly
involved N- and C-terminal extensions (Table 4, see foot-
notes). The mutational burden in each gene is proportional
to length. Although the CPXV-BR-219 ortholog SL-V70ter ovary; P, protein; MG, monoglyceride lipase; R, ribonucleotide; inter
xtracellular enveloped virion; PP, phosphoprotein; pol, polymerase; PKR
iral intermediate transcription factor; Myristyl P, myristylated protein; PW
sphat, nucleotide triphosphatase; CP, cysteine proteinase; VLTF, viral late
ttach, attachment; rif resist, rifampicin resistance; IF, inclusion factor; TM
9, and VACV-COP-C15L were present, but the residual coding sequences
section. This process removes ORFs that are vestiges of conserved ORFs
e removed 16 fragmented ORFs that were previously annotated, including
B18R, K1R, N2R, and R1R.
OS; BR, CPXV-Brighton Red; BSH, VARV-BSH; TIA, VACV-TIA; MVA
number of other OPVs that is not annotated in ZAI-96. Orthologs of this
egion that contains different lengths of an Asp–Thr repeat. A single InDel
termination codon in an otherwise complete ZAI-96 gene. Since a promote
hat polypeptides are likely to be made by the viruses of these two groups
tches to non-OPV proteins.,
,
,
,
,
,
r
.
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mutations per 100 aa that is identical to the 1.75 mutations
per 100 aa noted for this group of genes as a whole. It isTable 4
Mutation in SL-V70 and ZAI-96a members of the Virulence Ortholog familydifficult to evaluate the effect of a mutation(s) on protein
function without a detailed understanding of the relationship
of protein structure to function, but we have examined in
N. Chen et al. / Virology 340 (2005) 46–63 55greater detail 5 genes based on a likelihood that their
particular mutations may affect function (Table 4, grey
highlight).
ZAI-96 D10L, the ortholog of SL-V70 013, encodes a
host-range function necessary for optimal VACVand ECTV
replication in certain tissue culture lines, but was not
important for ECTV pathogenesis in the A strain of mouse
(Chen et al., 1993; Gillard et al., 1985). SL-V70 013 has a 4
bp deletion starting 29 bp upstream of the predicted start
codon. This mutation brings another upstream ATG in frame
and suggests the possibility of an N-terminal extension to
the SL-V70 protein that could affect function. This upstream
ATG, however, is 5V of a predicted promoter sequence
immediately upstream of the putative initiator ATG that is
conserved among OPV orthologs, so it is unknown whether
there will be an N-terminal extension for SL-V70 as
compared to ZAI-96. D14L encodes VCP-MPXV, an
ortholog of VACV complement-binding protein (VCP;
VACV-COP C3L). As compared to VCP-VACV, the VCP-
MPXV gene has a single nucleotide deletion leading to a
stop codon that terminates the predicted protein 13 aa into
the fourth complement control protein (CCP) module also
known as a short consensus repeat (Uvarova and Shchelku-
nov, 2001). All Congo basin MPXV isolates (CNG-8, ZAI-
V70, ZAI-77, ZAI-96, and ZAI-V79) that were acquired
over a 26-year period have an identical VCP-MPXV geneNotes to Table 4:
a The positions of all mutations can be found in the on-line file MPXV.bbb that
ZAI-96, COP-58, and WRAIR-61) in Base-By-Base format with supplemental an
b Functions thought to be essential for virus replication in standard tissue cu
replicating the genomic DNA, and assembling infectious virions, etc.) are highly
delineated in VACV-COP by gene F6L (position 38,015; in SL-V70 the ortholog is
positioned at 134,611). For each OPV, the remainder of the genome contains a mix
in particular cell types or the reservoir host, and others encode functions conserved
host. These functions are collectively referred to as the Virulence Ortholog fami
essential for virus replication in standard tissue culture lines.
c InDel is one deletion or insertion no matter how long of deletion/insertion.
d Conservative aa changes among the aa that have the similar structure: small and
(V, I, M, F, L), or large and polar (K, H, R, W, Y).
e SL-V70 003, 013, 157, and 169 have an N-terminal extension. SL-V70 020 an
OPV orthologs.
f SL-V70 014 has 8 copies of repeat element GAT (Asp) near the C-terminus in
among OPVs.
g ZAI-96 D13L and SL-V70 016 share 1 InDel and 5 substitutions, with 2 pro
h ZAI-96 D14L is completely absent from the corresponding region of the SL-
i There are no mutations within the serpin reactive-site loop.
j In SL-V70 029 has 2 InDels and 3 substitutions near the C-terminus that t
conservative, and 1 silent aa changes.
k SL-V70 141 has 2 subs that cause one aa change.
l One substitution located 5V to the N-terminus of ZAI-96 B4R causes MYT ch
N-terminal protein structure similar to SL-V70 157.
m SL-V70 158 has 3 copies of an N-terminal AATTCTTCC repeat element ins
N-terminus extension in ORF 158. The sequence of SL-V70 repeat element is
n The DNA sequence of ZAI-96 B10R is conserved in SL-V70 genome; howev
shift, splitting this ortholog into 72 aa and 118 aa fragments with the latter fragm
o DNA sequence of ZAI-96 B14R is conserved in SL-V70 genome; however, a
in SL-V70 cause a frame-shift splitting this ortholog into 163 aa and 132 aa frag
p SL-V70 168 has 1.5 copies of an ATCTCA repeat element near the C-terminus i
q The ortholog of surface glycoprotein in SL-V70 171 has 33 substitutions when
with one 2-base substitution causing 1 silent and a TYP aa change, and the 2 ot(Uvarova and Shchelkunov, 2001). This gene is completely
absent from the genomes of the three West African viruses
due to large DNA deletions. ZAI-96 B10R encodes a 221 aa
protein in the myxoma virus M-T4 virulence factor family
characterized by a C-terminal KDEL-like motif in a
potential ER-anchoring domain; it has orthologs in a variety
of poxviruses, but a frameshift mutation removes the C-
terminal two-thirds of the predicted protein in SL-V70. In
poxviruses, this protein is thought to play a role in
abrogating apoptosis of infected cells (Barry et al., 1997;
Hnatiuk et al., 1999). ORF B10R has orthologs in a variety
of poxviruses, but a frameshift mutation removes the C-
terminal two-thirds of the predicted protein in SL-V70. ZAI-
96 B14R encodes for an IL-1 binding protein that is
encoded by most OPVs. The role of this ortholog in
pathogenesis may be dependent on the route of inoculation
as one study found a vaccinia virus strain lacking the B14R
ortholog showed less virulence by the intracranial route,
while a second study using a similar mutant observed
enhanced virulence by the intranasal route of infection
(Spriggs et al., 1992; Alcami and Smith, 1992). This
ortholog in SL-V70 is disrupted by two frameshifts. ZAI-
96 B19R (SPI-1 gene) and SPI-1 orthologs of several OPVs
contain an unusual tandem repeat of CATTATATA imme-
diately upstream of the initiator ATG. SL-V70 169 has 7
copies of the repeat compared with 37, 27, 16 identicalcontains a multiple alignment of four complete MPXV genomes (SL-V70
notation.
lture cell lines (e.g. functions mainly necessary for transcribing mRNA
conserved in all sequenced OPVs, and map to a central conserved region
positioned at 35,132) to A25L (position 138,012; in SL-V70 the ortholog is
of genes, some are specifically tailored to the biology of the individual virus
among OPVs that may be essential for optimal replication and spread in the
ly. This set of genes is listed here minus genes that are or expected to be
non-polar (G, C, T, A, S), small and polar (E, D, N, Q), large and non-pola
d 029 have C-terminal extensions. These positions show variability in othe
stead of the 3 copies noted in ZAI-96 D11L. The number of repeats varies
ximal substitutions causing 1 aa change.
V70 genome because of a DNA sequence deletion.
ogether not only cause a length change, but also 2 conservative, 3 non
ange, and therefore cause 2-aa length change. Most OPVorthologs have an
tead of 2 copies found in ZAI-96. This results in a 3 aa extension near the
conserved in most OPVs.
er, a 2-base deletion in the 5V third of the SL-V70 ortholog causes a frame
ent out-of-frame.
1-base insertion in SL-V70 near the N-terminus and another 4-base deletion
ments.
nstead of the 4.5 copies found in ZAI-96 B17R and all other analyzed OPVs
compared to ZAI-96; 27 are 1-base substitutions, 3 are 2-base substitutions
her 2-base substitutions causing SYL and EYN changes.,
,
r
r
-
-
.
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ZAI-96 genomes, respectively. These repeats are positioned
between the predicted promoter region and the initiating
ATG codon of the SPI-1 genes; although there appears to be
an in-frame ATG upstream of the ZAI-96 ortholog, our
promoter prediction and primer extension data (Kettle et al.,
1995, 1997) indicate that the mRNA initiates 3V of this ATG.
It is not known, however, what effect the variable lengths of
5V untranslated mRNA, containing these repeats will have (if
any) on the level of SPI-1 protein production. Several other
OPV genomes (CPXV, VARV, CMLV, and VACV-WR)
possess a monomer of a similar sequence (CATTATTTA)
that may be related to the ancestral sequence of the SL-V70
repeat. The SPI-1 gene also has a ValYAla mutation at the
P12 position of the reactive center loop that would not be
expected to affect Serpin activity.
Members of the Virulence Ortholog family conserved in a
Congo basin isolate of MPXV and VARV
Since human monkeypox caused by Congo basin isolates
of MPXV is almost clinically indistinguishable from small-
pox, we further compared genomic sequences of MPXVand
VARV to determine if ZAI-96 D10L, D14L, B10R, B14R,
and B19R genes are conserved in VARV (Shchelkunov
et al., 1995). Because ZAI-96 D10L and B19R orthologs
are conserved in both West African and Congo Basin
isolates of MPXV as well as VARV-BSH-75 (Table 5), and
the consequences of their genetic differences among the
viruses are predicted to be minor, D10L and B19R are not
considered leading candidate as a determinant of virulence
for non-human primates and humans. The absence of
orthologs of ZAI-96 B10R and B14R in West African
isolates and VARV-BSH-75 also argues against a role of
these genes in ZAI-96 virulence. Thus, the presence of
VCP-MPXV orthologs in ZAI-96 and VARV-BSH-75, and
its absence in three West African viruses, makes VCP-
MPXV a leading candidate to explain the virulence differ-
ence between West African and Congo basin isolates.
Further inspection of Table 5 indicates that 11 genes, which
are lacking or truncated in VARV-BSH-75 or in the virulent
ZAI-96 may not be essential for orthopoxvirus virulence in
humans (grey highlight). And finally, all of the remaining
virulence genes that are conserved in both VARV-BSH-75
and ZAI-96 may indicate a subgroup of OPV virulence
genes important for human infections.
VCP-MPXV, a candidate MPXV virulence gene
The poxvirus inhibitors of complement enzymes, which
include VCP-MPXV, mimic the biologic activity of comple-
ment regulatory proteins (CRPs) that interact with C3b and
C4b to inhibit C3 and C5 convertases of the cascades
(Liszewski et al., 1996). This prevents a variety of events
downstream of complement activation including the depo-
sition of large amounts of C3 fragments, the release of theanaphylactoid and chemotactic mediators (C3a and C5a),
and the formation of the membrane attack complex (Isaacs
et al., 1992; Kotwal and Moss, 1988; McKenzie et al., 1992;
Sahu et al., 1998). Poxviral complement inhibitors consist
entirely of a series of four repeating CCP domains; the
CCPs are 30–40% identical to the human CRPs including
membrane co-factor protein (MCP; CD46), C4b-binding
protein, Factor H, and decay-accelerating factor (DAF;
CD55) and contain the regulatory-sites for C3b and C4b
(Herbert et al., 2002). Recently, Rosengard et al. (2002)
demonstrated that the VARV ortholog, VCP-VARV, was
nearly 100-fold and 6-fold more potent than VCP-VACV at
inactivating C4b and C3b, respectively, a finding that was
generally confirmed by others (Sfyroera et al., 2005). VCP-
MPXV, however, is unique among OPV orthologs in that it
has a truncated fourth CCP module (Fig. 3A). In spite of this
truncation, one preliminary study using a sheep red blood
cell hemolysis assay suggested that VCP-MPXV from a
Congo basin isolate had some complement enzyme inhib-
itory activity (Smith et al., 2000). To more fully establish the
role of VCP-MPXV as a possible virulence determinant for
the Congo basin MPXV isolates, its inhibitory activity for
human complement proteins was characterized.
To ascertain if VCP-MPXV retained complement regu-
latory function, recombinant VCP-MPXVwas expressed and
purified. AWestern blot demonstrated the predicted electro-
phoretic pattern including the faster relative mobility of the
non-reduced form (Fig. 3B). In the functional assessments,
VCP-MPXV retained regulatory activity for human C3b and
C4b. It bound human C3b and C4b (Fig. 3C), and also
demonstrated cofactor activity for both proteins (Fig. 3D)
(Liszewski et al., 1998). The latter assay analyzes the ability
of VCP-MPXV to serve as a cofactor for the serine protease
factor I (human) to cleave and thereby inactivate C3b and
C4b. The limited proteolytic cleavage fragments generated
through VCP-MPXV’s cofactor activity are similar in pattern
to those generated by mammalian homologs (Rosengard et
al., 2002). Indeed, two of these complement regulatory
proteins CD55 and CD46, also possess four CCPs, but
require the fourth CCP for complement regulatory function
(Liszewski and Atkinson, 1998). Thus, it is somewhat
surprisingly that VCP-MPXV, which lacks most of the fourth
CCP, retains complement regulatory activity. These results,
therefore, support VCP-MPXV as a candidate for a major
MPXV virulence gene in non-human primates.
The lack of a VCP-MPXV ortholog could make MPXV
virions and infected cells more susceptible to antibody and
complement lysis, which could diminish virus spread, and
lead to less severe disease. Consistent with this hypothesis,
patients in the U.S. 2003 outbreak, as compared to those
infected in the Congo basin, had significantly fewer skin
lesions (Damon, unpublished data). Also, the lesions
presented with a unique focal hemorrhagic necrosis, possibly
due to uncontrolled complement-mediated tissue destruction
at the site of infection (Reed et al., 2004). Increased local
tissue destruction was also noted in experimental studies in
Table 5
Presence of OPV Virulence Ortholog family members in monkeypox and variola viruses
a See footnote b of Table 4.
b We removed 29 fragmented ORFs that were previously annotated in VARV-BSH-75 genome, including A26L, A27L, A28L, A29L, A39L, A40R, A42R,
A43R, A47L, C1L, C7L, D17L, D16L, D13L, D10L, D9L, D8L, D1L, B20R, B19R, B14L, B11R, B7R, B4L, B3L, B2L, E7L, O3L, and J6R. The
reannotated VARV-BSH genome contains 162 ORFs. Our analysis suggests the VARV-BSH ORF D3L was likely not functional thus this ORFs was omitted
from our reannotation. The original annotation was described by Massung et al. (1994). These updated annotations are available from the POCsdb (http://
athena.bioc.uvic.ca).
c Fragment.
d VCP-MPXV has a single nucleotide deletion leading to a stop codon that terminates the protein 13 aa into the fourth CCP module and 43 aa from the C
terminus.
e Gene is missing.
N. Chen et al. / Virology 340 (2005) 46–63 57mice with the CPXV mutants lacking a VCP-MPXV
ortholog (Miller et al., 1995, 1997; Kotwal et al., 1998).
Formal proof that VCP-MPXV is a virulence gene will
require its deletion in a Congo basin MPXV isolate and
pathogenesis studies in non-human primates.Materials and methods
Viruses and cells
MPXV-SL-V70-I-266 (SL-V70) was obtained from the
crusts of lesions from a single case in Sierra Leone in 1970
(Lourie et al., 1972). The virus was passaged twice in BSC-40 cells. The MPXV-WRAIR-7-61 (WRAIR-61) isolate
was deposited with the American Type Culture Collection
(ATCC, catalogue number VR-267 and NIH bei collection
from which registered users can receive the virus) in May of
1962 by Major Stewart J. McConnell of WRAIR. WRAIR-
61 was isolated from a female cynomolgus monkey, B-39,
that was observed with a poxvirus-like infection 45 days
following whole-body irradiation of 350 rads (McConnell et
al., 1962). B-39 died 12 days after onset of disease.
WRAIR-61 was isolated from tissue culture in monkey
kidney cells, plaque-purified three times in rabbit kidney
cells, and passaged a further eight more times in rabbit
kidney cells prior to accession into the ATCC. At the ATCC,
the virus was further passage twice in Vero cells. ZAI-V79-
Fig. 3. VCP-MPXV structure and function. (A) Amino acid alignment of VCP-VARV and VCP-MPXV without signal peptides illustrating amino acid
differences and the premature termination of VCP-MPXV. (B) Western blot of non-reduced and reduced VCP-MPXV. Concentrated CHO supernatants
containing VCP-MPXV were electrophoresed in a 10% SDS-PAGE, transferred to nitrocellulose and developed with 1:5000 rabbit anti-VCP-VACVantibody.
(C) VCP-MPXV binds human C4b and C3b. A representative binding curve is shown. Ligands were coated onto microtiter plates followed by incubations with
media or VCP-MPXV. Binding was detected with rabbit anti-VCP-VACV antibody (1:5000). VCP-MPXV was quantified in an ELISA (Materials and
methods). (D) VCP-MPXV possesses cofactor activity for human C3b and C4b. Chemiluminescent cofactor assays were performed (with or without 10 ng
VCP-MPXV), biotinylated human C3b and C4b and 100 ng of human factor I followed by Western blot analysis. Arrows denote some of the major cleavage
fragments. Controls of VCP-MPXV without factor I did not show cleavage fragments (data not shown).
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severe case of human monkeypox in Zaire in 1979, and was
passaged sequentially once in LLCMK2 cells, twice in
BSC-40 cells, and two or three times in Vero cells (Zaucha
et al., 2001). MPXV-COP-58 (COP-58) was isolated in
1958 from scrapings of several papules on an infected
cynomolgus monkey from an outbreak of a vesicular
eruptive disease in a primate holding facility (von Magnus
et al., 1959). The virus was passaged an unknown number
of times on the chorioallantoic membrane of the chick egg
and in FL, LLCMK2, and BSC-40 cells. Vero, BSC-1, and
BSC-40 cells were grown in Eagle’s minimum essential
medium (EMEM; Bio-Whittaker, Walkersville, MD) con-taining 10% fetal bovine sera (Hyclone, Logan, UT), 2 mM
l-glutamine (GIBCO, Grand Island, NY), 100 U/ml of
penicillin (GIBCO, Grand Island, NY), and 100 Ag/ml of
streptomycin (GIBCO, Grand Island, NY). Virus plaque
assays were carried out on BSC-1 cell monolayers as
previously described (Chen et al., 1992). Comet assays were
carried out as for the plaque assay except 1% carboxyl
methyl cellulose was omitted from the overlay medium.
Monkey challenge experiment
Juvenile to adult, 1.6 to 4.7 kg, cynomolgus monkeys
(Macaca fascicularis) were challenged by small particle
N. Chen et al. / Virology 340 (2005) 46–63 59aerosol (mass median diameter of 1.2 Am) as described
previously (Zaucha et al., 2001). The husbandry and
experimental protocols were in accordance with Guide for
the Care and Use of Laboratory Animals. The facilities
were fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International.
Purification of monkeypox virus genomic DNA and DNA
sequencing
Five to eight monolayer cultures containing 2  107
Vero, BSC-40 or BSC-1 cells were infected with 0.1–5 pfu/
cell of each MPXV isolate in 5 ml of EMEM. After ¨1 h at
37 -C, cultures were supplemented with a further 10 ml of
prewarmed EMEM and incubated until maximum cyto-
pathic effect was observed (¨36 h). MPXV genomic DNA
was extracted from virions as described previously (Dhar et
al., 2004; Chen et al., 2003).
The genomes of SL-V70, WRAIR-61, and COP-58 were
sequenced as described previously for ectromelia virus
except that sequencing primers for the sequences of the
variable left and right-hand terminal regions were based on
ZAI-96 (Chen et al., 2003). Sequencing primers were
chosen approximately 450 bp apart on each strand to ensure
adequate overlap of sequencing reads. Both strands of each
fragment were sequenced and any gaps were closed by
primer-walking. Sequencing reactions were carried out
using CEQ 2000 Dye Terminator Cycle Sequencing with
Quick Start Kit (Beckman Coulter, Inc., Fullerton, CA) and
run on a CEQ 2000XL DNA Analysis System (Beckman
Coulter, Inc., Fullerton, CA).
Cloning and sequencing of heterogeneous regions in
WRAIR-61
The genome contains four extended runs of dA or dT
nucleotides that are heterogeneous in nature and therefore are
refractory to sequencing using PCR derived template DNA.
To resolve this problem, we cloned the heterogeneous
amplicons containing these regions and sequenced approx-
imately 10 clones for each region. These four regions were
PCR-amplified using the following primers. MLEA: MLEA-
5V (5V-ATAAGAATGCGGCCGCGTGTCTAGAAAAAAA-
TGTGTGACC-3V) and MLEA-3V (5V-TCCCCCGGG-
CATAGAACAGTGTCATCTATCG-3V); M1A: M1A-5V
(5 V-ATAAGAATGCGGCCGCGTTTAAGATAGTA-
TATTCTCTAG-3V) and M1A-3V (5V-TCCCCCGGGCAT-
GAGGACTCTACTTATTAG-3V); M18A: M18A-5V (5V-
ATAAGAATQGCGGCCGCGGAAAATACAAGTATAGA-
TACAACG-3V) and M18A-3V (5V-TCCCCCGGGTACTC-
CGTATTCATACTCG-3 V) ; M18B: M18B-5 V (5 V-
ATAAGAATGCGGCCGCGGAACTAACTATTACCAT-
GAATC-3V) and M18B-3V (5V-TCCCCCGGGTGTCT
AGAAAAAAATGTGTGACC-3V). The 5V and 3V primers
for each region contained NotI and SmaI recognition sites
(underlined), respectively. After digestion with NotI andSmaI, each region was cloned into similarly digested
pKT1012-gpt. pKT1012-gpt was derived from
pKT1012 (kindly provided by Dr. Kangla Tsung, Univer-
sity of California, San Francisco) by removal of the
fragment containing E. coli guanine phosphoribosyltrans-
ferase gene (gpt) under the control of P7.5 early VACV
promoter by digestion with NdeI and EcoRV, followed by
Klenow-blunting and self-ligation. Eleven plasmid clones
for the region MLEA, M1A, and M18B and 10 clones for
the region M18A were selected and separately sequenced
by primer walking.
Cloning and sequencing of heterogeneous regions in
SL-V70
Four heterogeneous regions (MSLEA,MS1A,MS2A, and
MS18A) of SL-V70 were PCR-amplified using the following
primers. MSLEA: MSLEA-5V (5V-ATAAGAATGCG-
GCCGCGTGTCTAGAAAAAAATGTGTGACC-3V) and
MSLEA-3V (5V-TCCCCCGGGCATAGAACAGTGTCATC-
TATCG-3V); MS1A: MS1A-5V (5V-ATAAGAATGCGGCQ
CGCGTACATCACTGTAAGCATGTCC-3V) and MS1A-3V
(5V-TCCCCCGGGATATGTAGCACAGACCAATTTC-3V);
MS2A: MS2A-5V (5V-ATAAGAATGCGGCCGCCTTT-
TATGTCAAGAAGGCACTGG-3V) and MS2A-3V (5V-
TCCCCCGGGTATCCCAATTTACGAGCCCGTTAACAA-
G-3V); MS18A: MS18A-5V (5V-ATAAGAATGCGGCCGCQ
GGAACTAACTATTACCATGAATC-3V) and MS18A-3V
(5V-TCCCCCGGGTGTCTAGAAAAAAATGTGTGACC-
3V). The 5V and 3V primers for each region contained NotI and
SmaI recognition sites (underlined), respectively. After
digestion with NotI and SmaI, each region was cloned as
described above. Eleven clones for the region MSLEA, 10
clones for the region MS1A, 8 clones for the region MS2A,
and 12 clones for the region MS18Awere selected, and their
plasmid DNA inserts were sequenced.
Cloning and sequencing of heterogeneous regions in
COP-58
Six heterogeneous regions (MCLEA, MC1A, MC15A,
MC16A, MC18A, and MC18B) of the genome of COP-58
were PCR-amplified using the following primers. MCLEA:
MCLEA-TOPO-5V (5V-CACCGAATGCGGCCGCGTGTC-
TAGAAAAAAATGTGTGACC-3V) and MCLEA-3V (5V-
TCCCCCGGGCATAGAACAGTGTCATCTATCG-3V);
MC1A: MC1A-TOPO-5V (5V-CACCGAATGCGGCCGCGQ
TTTAAGATAGTATATTCTCTAG-3V) and MC1A-3V (5V-
TCCCCCGGGCATGAGGACTCTACTTATTAG-3V);
MC15A: MC15A-TOPO-5V (5V-CACCGAATGCGGCCGC-
GATGAAAATCTTTGGATGGTTGC-3V) and MC15A-3V
(5V-TCCCCCGGGTAACCATCGTTAATTGGTCTTGC-
3V); MC16A: MC16A-TOPO-5V (5V-CACCGAATGCGGCC-
GCGAGTTCGGAAGTATGTCTGAC-3V) and MC16A-3V
(5V-TCCCCCGGGTAATCGATATTGGTCGTGTAG-3V);
MC18A: MC18A-TOPO-5V (5V-CACCGAATGCGGCCGC-
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3V (5V-TCCCCCGGGTACTCCGTATTCATACTCG-3V);
MC18B: MC18B-TOPO-5V (5V-CACCGAATGCGGCCGC-
GGAACTAACTATTACCATGAATC-3V) and MC18B-3V
(5V-TCCCCCGGGTGTCTAGAAAAAAATGTGTGACC-
3V). Each PCR product was cloned into pcDNA3.1D/V5-His-
TOPO using pcDNA3.1 Directional TOPO Expression Kit
according to the manufacture’s instructions (Invitrogen,
Carlsbad, California 92008). Fourteen clones for the region
MCLEA, 12 clones for the region MC1A, 11 clones for the
region MC15A, 12 clones for the region MC16A, 12 clones
for the region MC18A, and 12 clones for the region MC18B
were selected, and their plasmid DNA inserts were sequenced
as described above.
DNA sequence analysis
Assembly of the raw sequence data from the chromato-
grams for WRAIR-61 was performed using the Staden
software package on a Linux platform (Dear and Staden,
1991). Data were processed using Pregap4 (Ewing and
Green, 1998) and a consensus sequence was assembled and
edited using Gap4 (Bonfield and Staden, 1996; Bonfield et
al., 1995). The raw sequence data for SL-V70 and COP-58
was assembled using ContigExpress in Vector NTI Suite 8
(Invitrogen, Carlsbad, CA). An ORF was defined as a
continuous sequence that translated into a polypeptide
initiated by a methionine residue and extended for 60 or
more amino acids (aa) prior to a termination codon. Artemis
software (Mural, 2000) and Poxvirus Orthologous Clusters
database (POCsdb; (Ehlers et al., 2002) were used to detect
and annotate ORFs. Early and late promoter sequences in
genomes were identified using promoter sequence models
based upon sequence alignments of experimentally-verified
early and late vaccinia virus promoters (Wang and
Lefkowitz, unpublished data). BLASTP (Altschul et al.,
1997) was used to detect SL-V70 orthologs in other
poxvirus genomes contained in the POCsdb. In addition,
BLASTN, TBLASTN, and BLASTP searches were carried
out at the NCBI website to annotate some ORFs. Viral
Genome Organizer (VGO) software (Upton et al., 2000) and
Nucleotide-Amino Acid Alignment Program (NAP) (Huang
and Zhang, 1996) were used to compare nucleotide
sequences of fragmented ORF regions against the corre-
sponding predicted protein sequences of the longest
Chordopoxvirus ortholog. To calculate the primary nucleic
acid sequence identity shared between any two genomes,
complete genomic sequence alignments of every possible
pair-wise genomic combination of all available orthopoxvi-
rus sequences were constructed using the alignment
program LAGAN (Brudno et al., 2003). Percent identity
was calculated using the following formula: 100  (Number
of identical residues) / [(Number of identical residues) +
(Number of Mismatches) + (Number of InDels)]. An InDel
was defined as a single insertion–deletion event independ-
ent of the length of the resultant gap. Poxvirus genomesused for comparison are available at www.poxvirus.org. The
accession numbers are: NC_002520, Amsacta moorei
entomopoxvirus; NC_005337, Bovine papular stomatitis
virus; NC_003391, Camelpox virus, M-96; AY009089,
Camelpox virus, CMS; NC_005309, Canarypox virus
(ATCC VR-111); NC_003663, Cowpox virus, Brighton
Red; X94255, Cowpox virus, GRI-90; NC_004105, Ectro-
melia virus, Moscow; NC_002188, Fowlpox virus;
AJ581527, Fowlpox virus, HP-438 Munich; NC_003027,
Lumpy skin disease virus, Neethling 2490; AF409137,
Lumpy skin disease virus, Neethling Warmbaths LW;
AF409138, Lumpy skin disease virus, Neethling vaccine
LW 1959; NC_001993, Melanoplus sanguinipes ento-
mopoxvirus; NC_001731, Molluscum contagiosum virus;
NC_003310, Monkeypox virus, Zaire-96-I-16; NC_001132,
Myxoma virus, Lausanne; NC_005336, Orf virus, OV-
SA00; AY386263, Orf virus, OV-IA82; NC_001266, Rabbit
fibroma virus; AY484669, Rabbitpox virus, Utrecht;
AX754989, sequence 1 from Patent WO03006654;
NC_004002, Sheeppox virus, TU-V02127; NC_003389,
Swinepox virus, 17077-99; NC_001559, Vaccinia virus,
strain Copenhagen; U94848, Modified vaccinia virus, strain
Ankara; AY243312, Vaccinia virus, strain Western Reserve;
L22579, Variola major virus, Bangladesh-1975;
NC_001611, Variola major virus, India-1967; NC_005179,
Yaba monkey tumor virus; NC_002642, Yaba-like disease
virus; Y16780, Variola minor virus, Garcia-1966.
Sequence alignment and phylogenetic analysis
Sequence alignments were generated using a combi-
nation of the programs MAVID and Multi-LAGAN (Bray
and Pachter, 2004; Brudno et al., 2003). Extensive hand
editing was also used to optimize the alignment.
Phylogenetic analysis was carried out using an ¨138
kbp conserved central region of completely sequenced
genomes of various orthopoxvirus species. The left end
of the alignment extends from gene C7L of vaccinia
virus strain Copenhagen (VACV-COP, position 18,805 of
the genome) to A51R at the right end (position 157,688).
Evolutionary relationships were solved using the Branch-
and-Bound search method with maximum parsimony as
the optimality criterion. Bootstrap resampling confidence
values on 1000 replicates were also calculated using
Branch-and-Bound with maximum parsimony. Branch
lengths are proportional to the number of sequence
changes along each branch. All evolutionary relationships
were estimated using the program PAUP* version 4.0b10
(http://paup.csit.fsu.edu/).
Production and functional assessment of VCP-MPXV
activity
The VCP-MPXV gene was PCR amplified using
genomic DNA from Congo basin isolate MPXV-ZAI-V70-
I-823 using the following primers: VCP-MPXV-5V (5V-ATG-
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3V) and VCP-MPXV-3V (5V-TTAAGCCGCTAGAAGTTTT-
CCGTTTGATATAG-3V) and cloned into the pCR\-Blunt
vector (Invitrogen, Carlsbad, CA). A clone was isolated and
the insert was shown by DNA sequencing to be identical to
the VCP-MPXV gene of ZAI-96. The DNA was further
subcloned into the EcoR1 site of plasmid pSG5 (Stratagene,
La Jolla, CA). A construct also was prepared in pSG5 that
added a cleavable (enterokinase: Asp–Asp–Asp–Asp–
Lys) 6 histidine tag using the QuikChange\ Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) with the
following two complementary oligonucleotides each under-
lining the area of recognition (5V-CGGAAAACTTC-
TAGCGGCTGACGATGA CGATAAGCATCATCATCAT-
CATCAT TAACCTGAATTCGGATCCAG-3V and 5V-
CTGGATCCGAATTCAGGTTAATGATGATGATGATGA-
TGCTTATCGTCATCGTCAGCCGCTAGAAGTTTTCCG-
3V). DNAs from the clones in pSG5 with the enterokinase/
6 histidine tag (VCP-MPXV-EH) and without (VCP-
MPXV) were expressed transiently in Chinese hamster
ovary (CHO) cells and the supernatants concentrated.
Tagged and untagged versions of VCP-MPXV had similar
activity. VCP-MPXV-EH supernatants were purified on
ProBondi Resin (Invitrogen, Carlsbad, CA). VCP-MPXV
protein concentrations were estimated in an ELISA assay.
Briefly, the capture antibody (5A10, a cross reacting VCP-
VARV mAb, gift of Ariella Rosengard) was coated at 5 Ag/
ml overnight at 4 -C and then blocked for 1 h at 37 -C (1%
BSA and 0.1% Tween-20 in PBS). Dilutions of concentrated
samples and VCP-VACV (as a standard) were incubated for
1 h at 37 -C and then washed with PBS containing 0.05%
Tween 20. Rabbit anti-VCP-VACV antiserum (1:5000; gift
of Girish Kotwal) was applied for 1 h at 37 -C. After
washing, horseradish peroxidase-coupled donkey anti-rabbit
IgG (Jackson ImmunoResearch Laboratories, West Grove,
PA) was added and incubated for 1 h at 37 -C. After
washing, TMB substrate (Pierce, Rockford, IL) was added
and absorbance (630 nm) assessed in an ELISA reader. For
Western blot assays, the supernatants or purified proteins
were electrophoresed in non-reduced and reduced 10%
SDS-PAGE, transferred to nitrocellulose, and probed with
1:5000 rabbit anti-VCP-VACVantibody, followed by horse-
radish peroxidase goat anti-rabbit IgG and developed with
ECL Plus (Amersham, Piscataway, NJ). To characterize
VCP-MPXV binding to human C4b and C3b, the ligands
were coated onto microtiter plates (5 Ag/ml in PBS)
followed by incubations with media or VCP-MPXV. Bind-
ing was detected with rabbit anti-VCP-VACV antibody
(1:5000) as described above. Chemiluminescent cofactor
assays were performed in the presence or absence of 10 ng
VCP-MPXV-EH, biotinylated human C3b and C4b and
human factor I in 10 mM Tris pH 7.4 with 25 mM sodium
chloride (Liszewski et al., 1998). Following 1 h incubation
at 37 -C, samples were reduced, run on 10% SDS-PAGE,
transferred to nitrocellulose, and probed with avidin-horse-
radish peroxidase. Final signal development used ECL Plus.Sequence availability
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